Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
- 1 February 1998
- journal article
- clinical trial
- Vol. 4 (2), 357-60